Scrip
Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
09 December 2009
Asher Mullard
Please Login to read the full article.
09 December 2009
Asher Mullard
Bayer and
Johnson & Johnson's Xarelto (rivaroxaban) faced a further setback this week after Bayer announced that despite previous guidance it would not respond to the US FDA's rejection of the drug before the end of they year. Bayer shares have fallen by 4% in two days, to around €52.02 on...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Face-to-face with Abingworth's Stephen Bunting:we've had time to adapt to tough markets
- Proximagen looks to M&A to expand pipeline
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
